Market capitalization | $13.21m |
Enterprise Value | $26.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 17.96 |
P/S ratio (TTM) P/S ratio | 9.11 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -63.20% |
Revenue (TTM) Revenue | $1.45m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
1 Analyst has issued a forecast HCW Biologics Inc:
1 Analyst has issued a forecast HCW Biologics Inc:
Mar '25 |
+/-
%
|
||
Revenue | 1.45 1.45 |
63%
63%
|
|
Gross Profit | -1.01 -1.01 |
1,363%
1,363%
|
|
EBITDA | -12 -12 |
57%
57%
|
EBIT (Operating Income) EBIT | -13 -13 |
54%
54%
|
Net Profit | -25 -25 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
HCW Biologics, Inc. operates as a holding company which engages in the research and development of immunotherapies. It focuses on cancer and aging-associated diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.
Head office | United States |
CEO | Hing Wong |
Employees | 36 |
Founded | 2018 |
Website | www.hcwbiologics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.